Recently, the shortlist for the highly anticipated Facility of the Year Awards (FOYA) was officially announced at the 2026 Future Facilities Conference held by the International Society of Pharmaceutical Engineers (ISPE) in San Diego, USA. Heprui Pharmaceutical was successfully selected for its newly built pre filled formulation intelligent manufacturing project located in Pingshan, Shenzhen, becoming the only Chinese enterprise among the top 16 companies in the world this year. It competed with multinational pharmaceutical giants such as Sanofi, AstraZeneca, Bayer, Johnson&Johnson, Merck, and others for the highest honor known as the "Oscar of Medical Facilities". The FOYA Award was established in 2005 and is the only global award in the pharmaceutical industry that focuses on "facilities and engineering". Every year, the most representative pharmaceutical facility projects are selected globally and rigorously evaluated from five dimensions: innovation, engineering integrity, compliance, sustainable operation, and social impact. This award has long been regarded as an international benchmark for measuring the engineering management and intelligent manufacturing capabilities of pharmaceutical companies. The nomination of Hepprec this time is not only a concentrated reflection of the company's own industrial chain construction, manufacturing capacity improvement, and global trust accumulation, but also regarded as a landmark event for China's pharmaceutical industry to stand at the center of the global engineering stage. The intelligent manufacturing project for pre filled and sealed formulations in Hepuipingshan is one of the core components of its global formulation strategy layout. This project is fully integrated with the FOYA review system and global high standards, from design concept to technical implementation. The project fully implements the concept of "quality comes from design", from production line configuration, personnel flow to process parameters, all of which are based on passing the global Good Manufacturing Practice (GMP) audit, achieving embedded and systematic quality control. Meanwhile, relying on the vertical integration capability of the heparin industry chain, the project has achieved full process traceability from raw material collection, API manufacturing to formulation filling. Each factory produced enoxaparin sodium injection has a unique identification code, which is associated with all key production and quality inspection data. In addition, the project also integrates energy-saving facilities such as energy management systems and water storage cooling, and accelerates the construction of photovoltaic power generation systems. It is expected that after being put into use in 2026, the proportion of green energy will be further increased, fulfilling the commitment to sustainable development. It is reported that after the new production line is put into operation, the annual production capacity of heparin sodium preparations by Heparin will increase to 550 million units, covering nearly 800 SKUs (inventory units), which can support stable global supply under different regulatory requirements. At present, its core products have been approved in 78 countries and regions, sold in over 50 countries, and the group's overseas business revenue accounts for over 90%. (New Society)